On Tuesday, Summit Therapeutics Inc (NASDAQ: SMMT) opened higher 2.83% from the last session, before settling in for the closing price of $17.99. Price fluctuations for SMMT have ranged from $2.10 to $33.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -8.94% over the last five years. Company’s average yearly earnings per share was noted -38.25% at the time writing. With a float of $114.92 million, this company’s outstanding shares have now reached $737.63 million.
The firm has a total of 159 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Summit Therapeutics Inc (SMMT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Summit Therapeutics Inc is 84.42%, while institutional ownership is 12.62%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 26 ’24, when Company’s Chief Executive Officer bought 30,000 for $3.75, making the entire transaction worth $112,500. This insider now owns 30,000 shares in total.
Summit Therapeutics Inc (SMMT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -38.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -28.86% during the next five years compared to -10.52% drop over the previous five years of trading.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Check out the current performance indicators for Summit Therapeutics Inc (SMMT). In the past quarter, the stock posted a quick ratio of 10.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Analysing the last 5-days average volume posted by the [Summit Therapeutics Inc, SMMT], we can find that recorded value of 2.66 million was better than the volume posted last year of 2.53 million. As of the previous 9 days, the stock’s Stochastic %D was 24.12%. Additionally, its Average True Range was 1.63.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 23.89%, which indicates a significant decrease from 25.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.30% in the past 14 days, which was higher than the 82.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.93, while its 200-day Moving Average is $16.24. Now, the first resistance to watch is $19.11. This is followed by the second major resistance level at $19.71. The third major resistance level sits at $20.56. If the price goes on to break the first support level at $17.66, it is likely to go to the next support level at $16.81. Should the price break the second support level, the third support level stands at $16.21.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
There are currently 737,680K shares outstanding in the company with a market cap of 13.65 billion. Presently, the company’s annual sales total 0 K according to its annual income of -221,320 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -61,200 K.
